Top broker tips Australian Clinical Labs (ASX:ACL) share price to shoot higher

This broker thinks ASX investors should get better acquainted with this ASX share…

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian Clinical Labs Ltd (ASX: ACL) share price is pushing higher on Monday.

In afternoon trade, the pathology services provider's shares are up 2% to $3.76.

Despite this gain, the Australian Clinical Labs share price is still trading 6% below its May IPO price of $4.00.

Why is the Australian Clinical Labs share price pushing higher?

Investors have been buying the company's shares this morning following the release of a bullish broker note out of Goldman Sachs.

According to the note, the broker has initiated coverage on the company with a buy rating and $4.80 price target. Based on the current Australian Clinical Labs share price, this implies potential upside of almost 28% over the next 12 months.

Goldman Sachs was the joint lead manager and underwriter of the company's IPO last month.

What did Goldman Sachs say?

Goldman believes that Australian Clinical Labs will benefit from a series of operational investments. These include its unified Laboratory Information System and upgraded central laboratory network.

In addition to this, over the long term, the broker expects the company's growth to track around market growth of 3% to 5%. However, it sees scope for the company to achieve the upper end of this range if it executes well on growth strategies in New South Wales and Queensland.

Furthermore, it notes that with leverage of 1.0x net debt/EBITDA, there is the opportunity to accelerate its growth through acquisitions.

Attractive valuation

Another reason to be positive on the Australian Clinical Labs share price is its valuation. Particularly in comparison to rivals Healius Ltd (ASX: HLS) and Sonic Healthcare Limited (ASX: SHL).

Goldman commented: "We believe current trading multiples are undemanding: FY22E EV/EBITDA 6.8x (vs. HLS 9.1x; SHL 11.3x) and FY22E EV/EBIT: 16.2x (vs. HLS 20.1x; SHL 17.6x)."

"Whilst the forward EBIT growth profile of +4% (FY22-25E) is less attractive than HLS (+7%), it is above SHL (+2%), and hence in-line with the peer average. ASX 200 HC [healthcare sector] trades on 21x EBITDA for +8% CAGR," it added.

This could make it worth considering if you're looking for healthcare options.

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Share Market News

Which ASX sectors led the pack in March, according to Macquarie?

It was a volatile month for ASX 200 shares...

Read more »

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was rocked by 'Liberation Day' this Thursday.

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Superannuation

AustralianSuper sticks with US stocks despite recent turmoil

AustralianSuper’s head of international equities says they won't be shifting focus to Europe.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Opinions

2 compelling ASX shares I'd buy now following the tariff stock market pain

These investments could make excellent buys in the current market sell-off.

Read more »

Child drinking milk out of a glass.
Share Gainers

Guess which ASX All Ords share just rocketed 12% in today's crashing market?

This ASX All Ords share is surging today despite the Trump tariff market turmoil. But why?

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Astral, Newmont, Ramelius, and Synlait shares are defying the market selloff and rising

These shares are rising despite the market weakness today. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Breville, Cettire, and Treasury Wine shares are dropping today

These shares are having a tough time on Thursday. But why?

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

How are ASX 200 investors responding to the new Trump tariffs today?

Australia didn’t escape the new Trump tariffs. Here’s how ASX investors are repositioning today.

Read more »